Join

Compare · BX vs HQL

BX vs HQL

Side-by-side comparison of Blackstone Inc. (BX) and abrdn Life Sciences Investors Shares of Beneficial Interest (HQL): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both BX and HQL operate in Investment Managers (Finance), so they compete in similar markets.
  • BX is the larger of the two at $92.54B, about 197.8x HQL ($467.9M).
  • Over the past year, BX is down 8.4% and HQL is up 50.3% - HQL leads by 58.7 points.
  • BX has hit the wire 7 times in the past 4 weeks while HQL has been quiet.
  • BX has more recent analyst coverage (25 ratings vs 0 for HQL).
PerformanceBX-8.42%HQL+50.33%
2025-05-07+0.00%2026-05-06
MetricBXHQL
Company
Blackstone Inc.
abrdn Life Sciences Investors Shares of Beneficial Interest
Price
$124.71+1.60%
$18.22+1.96%
Market cap
$92.54B
$467.9M
1M return
+10.60%
+8.16%
1Y return
-8.42%
+50.33%
Industry
Investment Managers
Investment Managers
Exchange
NYSE
NYSE
IPO
2007
1992
News (4w)
7
0
Recent ratings
25
0
BX

Blackstone Inc.

The Blackstone Group Inc. is an alternative asset management firm specializing in real estate, private equity, hedge fund solutions, credit, secondary funds of funds, public debt and equity and multi-asset class strategies. The firm typically invests in early-stage companies. It also provide capital markets services. The real estate segment specializes in opportunistic, core+ investments as well as debt investment opportunities collateralized by commercial real estate, and stabilized income-oriented commercial real estate across North America, Europe and Asia. The firm's corporate private equity business pursues transactions throughout the world across a variety of transaction types, including large buyouts,special situations, distressed mortgage loans, mid-cap buyouts, buy and build platforms, which involves multiple acquisitions behind a single management team and platform, and growth equity/development projects involving significant majority stakes in portfolio companies and minority investments in operating companies, shipping, real estate, corporate or consumer loans, and alternative energy greenfield development projects in energy and power, property, dislocated markets, shipping opportunities, financial institution breakups, re-insurance, and improving freight mobility, financial services, healthcare, life sciences, enterprise tech and consumer, as well as consumer technologies. The fund considers investment in Asia and Latin America. It has a three year investment period. Its hedge fund business manages a broad range of commingled and customized fund solutions and its credit business focuses on loans, and securities of non-investment grade companies spread across the capital structure including senior debt, subordinated debt, preferred stock and common equity. The Blackstone Group Inc. was founded in 1985 and is headquartered in New York, New York with additional offices across Asia, Europe and North America.

HQL

abrdn Life Sciences Investors Shares of Beneficial Interest

Tekla Life Sciences Investors is a closed-ended equity mutual fund launched and managed by Tekla Capital Management LLC. The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries. The fund primarily invests in growth stocks of small cap companies. It employs fundamental analysis with a focus on factors such as market position for services or products, experience of business management, technological expertise, and the ability either to generate funds internally to finance growth or to secure outside sources of capital to create its portfolio. The fund benchmarks the performance of its portfolio against the NASDAQ Biotech Index and the S&P 500 Index. It was formerly known as H&Q Life Sciences Investors fund. Tekla Life Sciences Investors was formed on February 20, 1992 and is domiciled in the United States.

Latest BX

Latest HQL